PR status (positive, PR+; negative, PR-) in breast cancer is determined through immunohistochemical analysis. ER+ and PR+ are found in 60-70% of cases, with better prognosis due to hormone-targeted therapy. PR status helps predict a patient's response to hormone therapy. Here, ESR1 is linked to breast cancer.